Title:
ANTI-IGF-I RECEPTOR ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2018/221521
Kind Code:
A1
Abstract:
The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.
Inventors:
EGUCHI HIROSHI (JP)
TANOKURA AKIRA (JP)
TAKAGI KENICHIRO (JP)
KATO HIROTSUGU (JP)
YAMAMURA SATOSHI (JP)
NAMIKI NAOKO (JP)
TANOKURA AKIRA (JP)
TAKAGI KENICHIRO (JP)
KATO HIROTSUGU (JP)
YAMAMURA SATOSHI (JP)
NAMIKI NAOKO (JP)
Application Number:
PCT/JP2018/020581
Publication Date:
December 06, 2018
Filing Date:
May 29, 2018
Export Citation:
Assignee:
TEIJIN PHARMA LTD (JP)
International Classes:
C07K16/28; A01K67/027; A61K35/12; A61K35/34; A61K35/76; A61K39/395; A61K45/00; A61K48/00; A61P1/04; A61P1/12; A61P1/16; A61P1/18; A61P3/00; A61P3/04; A61P3/10; A61P9/00; A61P9/10; A61P9/14; A61P11/00; A61P13/08; A61P13/10; A61P13/12; A61P15/00; A61P17/02; A61P17/06; A61P19/08; A61P19/10; A61P21/02; A61P21/04; A61P25/00; A61P27/02; A61P27/16; A61P35/00; A61P35/02; A61P37/06; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/13; C12N15/63; C12P21/08
Domestic Patent References:
| WO2009121759A2 | 2009-10-08 | |||
| WO2013180238A1 | 2013-12-05 |
Foreign References:
| JP2010538012A | 2010-12-09 | |||
| JP2011518778A | 2011-06-30 |
Other References:
SOOS, MA. ET AL.: "A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity", J. BIOL. CHEM., vol. 267, no. 18, 25 June 1992 (1992-06-25), pages 12955 - 12963, XP055563002, ISSN: 0021-9258
XIONG, L. ET AL.: "Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor", PROC. NATL. ACAD. SCI. U. S. A., vol. 89, no. 12, 1992, pages 5356 - 5360, XP002423617, ISSN: 0027-8424
CALZONE, FJ. ET AL.: "Epitope-specific mechanisms of IGF1R inhibition by ganitumab", PLOS ONE, vol. 8, no. 2, February 2013 (2013-02-01), pages 12, XP055229612, ISSN: 1932-6203
JONES, RA. ET AL.: "Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation", ONCOGENE, vol. 26, no. 11, 4 March 2007 (2007-03-04), pages 1636 - 1644, XP055563006, ISSN: 0950-9232
RUNNELS, HA. ET AL.: "Human monoclonal antibodies to the insulin-like growth factor 1 receptor inhibit receptor activation and tumor growth in preclinical studies", ADV. THER., vol. 27, no. 7, 14 June 2010 (2010-06-14), pages 458 - 475, XP002751208, ISSN: 0741-238X
OHLSSON, C. ET AL.: "The role of liver-derived insulin-like growth factor-I", ENDOCR REV, vol. 30, no. 5, 2009, pages 494 - 535
KAVRAN, J.M. ET AL.: "How IGF-I activates its receptor", ELIFE, 2014, pages 3
BAILYES, E.M. ET AL.: "Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting", BIOCHEM J, vol. 327, 1997, pages 209 - 15
PANDINI, G. ET AL.: "Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved", J BIOL CHEM, vol. 277, no. 42, 2002, pages 39684 - 95
ORPHANPACIFIC, IF., 2015
FUKUSHIMA, T. ET AL.: "Phosphatidylinositol 3-kinase (PI3K) activity bound to insulin-like growth factor-I (IGF-I) receptor, which is continuously sustained by IGF-I stimulation, is required for IGF-I-induced cell proliferation", J BIOL CHEM, vol. 287, no. 35, 2012, pages 29713 - 21
SCHIAFFINO, S.C. MAMMUCARI: "Regulation of skeletal muscle growth by the IGF-I-Akt/PKB pathway: insights from genetic models", SKELET MUSCLE, vol. 1, 2011, pages 4, XP021091525, DOI: 10.1186/2044-5040-1-4
BOONEN, S. ET AL.: "Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study", J CLIN ENDOCRINOL METAB, vol. 87, no. 4, 2002, pages 1593 - 9
BARTON-DAVIS, E.R. ET AL.: "Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function", PROC NATL ACAD SCI U S A, vol. 95, no. 26, 1998, pages 15603 - 7, XP002907664, DOI: 10.1073/pnas.95.26.15603
LAMBERTS, S.W.A.W. VAN DEN BELDA.J. VAN DER LELY: "The endocrinology of aging", SCIENCE, vol. 278, no. 5337, 1997, pages 419 - 24
MUSARO, A. ET AL.: "Localized IGF-I transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle", NAT GENET, vol. 27, no. 2, 2001, pages 195 - 200, XP001199471, DOI: 10.1038/84839
TEMEL, J.S. ET AL.: "Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomized, double-blind, phase 3 trials", LANCET ONCOL, vol. 17, no. 4, 2016, pages 519 - 31, XP029483266, DOI: 10.1016/S1470-2045(15)00558-6
GLASS, D.J.: "Signaling pathways perturbing muscle mass", CURR OPIN CLIN NUTR METAB CARE, vol. 13, no. 3, 2010, pages 225 - 9
LEE, S.J.A.C. MCPHERRON: "Regulation of myostatin activity and muscle growth", PROC NATL ACAD SCI USA, vol. 98, no. 16, 2001, XP002957299, DOI: 10.1073/pnas.151270098
AMIROUCHE, A. ET AL.: "Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle", ENDOCRINOLOGY, vol. 150, no. 1, 2009, pages 286 - 94
WOODHOUSE, L. ET AL.: "A Phase 2 Randomized Study Investigating the Efficacy and Safety of Myostatin Antibody LY2495655 versus Placebo in Patients Undergoing Elective Total Hip Arthroplasty", J FRAILTY AGING, vol. 5, no. 1, 2016, pages 62 - 70
BECKER, C. ET AL.: "Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomized, phase 2 trial", LANCET DIABETES ENDOCRINOL, vol. 3, no. 12, 2015, pages 948 - 57
AMATO, A.A. ET AL.: "Treatment of sporadic inclusion body myositis with bimagrumab", NEUROLOGY, vol. 83, no. 24, 2014, pages 2239 - 46, XP055251705, DOI: 10.1212/WNL.0000000000001070
CUTFIELD, W. S. ET AL.: "Non-compliance with growth hormone treatment in children is common and impairs linear growth", PLOS ONE., vol. 6, no. 1, 2011, pages e16223
BANG, P. ET AL.: "Identification and management of poor response to growth-promoting therapy in children with short stature", CLIN ENDOCRINOL (OXF, vol. 77, no. 2, 2012, pages 169 - 181
PUCHE, J.E.I. CASTILLA-CORTAZAR: "Human conditions of insulin-like growth factor-I (IGF-I) deficiency", J TRANSL MED, vol. 10, 2012, pages 224, XP021134203, DOI: 10.1186/1479-5876-10-224
KOHN, A.D. ET AL.: "Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation", J BIOL CHEM, vol. 271, no. 49, 1996, pages 31372 - 8, XP002558471, DOI: 10.1074/jbc.271.49.31372
CHO, H. ET AL.: "Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta", SCIENCE, vol. 292, no. 5522, 2001, pages 1728 - 31, XP002974608, DOI: 10.1126/science.292.5522.1728
GREEN, C.J. ET AL.: "Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake", J BIOL CHEM, vol. 283, no. 41, 2008, pages 27653 - 67, XP055102593, DOI: 10.1074/jbc.M802623200
GARCIA-FERNANDEZ, M. ET AL.: "Low doses of insulin-like growth factor I improve insulin resistance, lipid metabolism, and oxidative damage in aging rats", ENDOCRINOLOGY, vol. 149, no. 5, 2008, pages 2433 - 42
PUCHE, J.E. ET AL.: "Low doses of insulin-like growth factor-I induce mitochondrial protection in aging rats", ENDOCRINOLOGY, vol. 149, no. 5, 2008, pages 2620 - 7
JOSEPH D'ERCOLE, A.P. YE: "Expanding the mind: insulin-like growth factor I and brain development", ENDOCRINOLOGY, vol. 149, no. 12, 2008, pages 5958 - 62
ABUZZAHAB, M.J. ET AL.: "IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation", N ENGL J MED, vol. 349, no. 23, 2003, pages 2211 - 22
WOODS, K.A. ET AL.: "Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene", N ENGL J MED, vol. 335, no. 18, 1996, pages 1363 - 7
PEREZ, R. ET AL.: "Mitochondrial protection by low doses of insulin-like growth factor- I in experimental cirrhosis", WORLD J GASTROENTEROL, vol. 14, no. 17, 2008, pages 2731 - 9
KANG, B.P. ET AL.: "IGF-I inhibits the mitochondrial apoptosis program in mesangial cells exposed to high glucose", AM J PHYSIOL RENAL PHYSIOL, vol. 285, no. 5, 2003, pages F1013 - 24
BHASKAR, V. ET AL.: "A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control", DIABETES, vol. 61, no. 5, 2012, pages 1263 - 71, XP055325190, DOI: 10.2337/db11-1578
XIONG, L. ET AL.: "Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor", PROC NATL ACAD SCI USA, vol. 89, no. 12, 1992, pages 5356 - 60, XP002423617, DOI: 10.1073/pnas.89.12.5356
RUNNELS, H.A. ET AL.: "Human monoclonal antibodies to the insulin-like growth factor 1 receptor inhibit receptor activation and tumor growth in preclinical studies", ADV THER, vol. 27, no. 7, 2010, pages 458 - 75, XP002751208, DOI: 10.1007/s12325-010-0026-5
SOOS, M.A. ET AL.: "A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity", J BIOL CHEM, vol. 267, no. 18, 1992, pages 12955 - 63, XP002477383
KATO, H. ET AL.: "Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3", J BIOL CHEM, vol. 268, no. 4, 1993, pages 2655 - 61, XP008114108
ATZORI,F.: "A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors", CLIN CANCER RES., vol. 17, no. 19, 2011, pages 6304 - 12
DE BONO J.S. ET AL.: "Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer", CLIN CANCER RES., vol. 20, no. 7, 2014, pages 1925 - 34
TAKETO TANAKA ET AL., KEIO J. MED., vol. 60, pages 37 - 46
KABAT ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 147, no. 5, 1991, pages 1709 - 1719
AL-LAZIKANI ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 273, no. 4, 1997, pages 927 - 948
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1992, DIANE PUBLISHING
EDELMAN ET AL., PROC. NATL. ACAD. SCI USA, vol. 63, 1969, pages 78 - 85
MILSTEIN ET AL., NATURE (ENGLAND, vol. 305, no. 5934, 6 October 1983 (1983-10-06), pages 537 - 540
MILSTEIN ET AL., NATURE, vol. 305, no. 5934, 1983, pages 537 - 540
TAKETO TANAKA ET AL., THE KEIO JOURNAL OF MEDICINE, vol. 60, pages 37 - 46
"University of the Sciences in Philadelphia", 2000, LIPPINCOTT WILLIAMS & WILKINS, article "Remington: The Science and Practice of Pharmacy, 20th EDITION"
H. JIANGX. GE, JOURNAL OF ANIMAL SCIENCE, vol. 92, 2014, pages 21 - 29
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 497
See also references of EP 3636670A4
XIONG, L. ET AL.: "Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor", PROC. NATL. ACAD. SCI. U. S. A., vol. 89, no. 12, 1992, pages 5356 - 5360, XP002423617, ISSN: 0027-8424
CALZONE, FJ. ET AL.: "Epitope-specific mechanisms of IGF1R inhibition by ganitumab", PLOS ONE, vol. 8, no. 2, February 2013 (2013-02-01), pages 12, XP055229612, ISSN: 1932-6203
JONES, RA. ET AL.: "Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation", ONCOGENE, vol. 26, no. 11, 4 March 2007 (2007-03-04), pages 1636 - 1644, XP055563006, ISSN: 0950-9232
RUNNELS, HA. ET AL.: "Human monoclonal antibodies to the insulin-like growth factor 1 receptor inhibit receptor activation and tumor growth in preclinical studies", ADV. THER., vol. 27, no. 7, 14 June 2010 (2010-06-14), pages 458 - 475, XP002751208, ISSN: 0741-238X
OHLSSON, C. ET AL.: "The role of liver-derived insulin-like growth factor-I", ENDOCR REV, vol. 30, no. 5, 2009, pages 494 - 535
KAVRAN, J.M. ET AL.: "How IGF-I activates its receptor", ELIFE, 2014, pages 3
BAILYES, E.M. ET AL.: "Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting", BIOCHEM J, vol. 327, 1997, pages 209 - 15
PANDINI, G. ET AL.: "Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved", J BIOL CHEM, vol. 277, no. 42, 2002, pages 39684 - 95
ORPHANPACIFIC, IF., 2015
FUKUSHIMA, T. ET AL.: "Phosphatidylinositol 3-kinase (PI3K) activity bound to insulin-like growth factor-I (IGF-I) receptor, which is continuously sustained by IGF-I stimulation, is required for IGF-I-induced cell proliferation", J BIOL CHEM, vol. 287, no. 35, 2012, pages 29713 - 21
SCHIAFFINO, S.C. MAMMUCARI: "Regulation of skeletal muscle growth by the IGF-I-Akt/PKB pathway: insights from genetic models", SKELET MUSCLE, vol. 1, 2011, pages 4, XP021091525, DOI: 10.1186/2044-5040-1-4
BOONEN, S. ET AL.: "Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study", J CLIN ENDOCRINOL METAB, vol. 87, no. 4, 2002, pages 1593 - 9
BARTON-DAVIS, E.R. ET AL.: "Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function", PROC NATL ACAD SCI U S A, vol. 95, no. 26, 1998, pages 15603 - 7, XP002907664, DOI: 10.1073/pnas.95.26.15603
LAMBERTS, S.W.A.W. VAN DEN BELDA.J. VAN DER LELY: "The endocrinology of aging", SCIENCE, vol. 278, no. 5337, 1997, pages 419 - 24
MUSARO, A. ET AL.: "Localized IGF-I transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle", NAT GENET, vol. 27, no. 2, 2001, pages 195 - 200, XP001199471, DOI: 10.1038/84839
TEMEL, J.S. ET AL.: "Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomized, double-blind, phase 3 trials", LANCET ONCOL, vol. 17, no. 4, 2016, pages 519 - 31, XP029483266, DOI: 10.1016/S1470-2045(15)00558-6
GLASS, D.J.: "Signaling pathways perturbing muscle mass", CURR OPIN CLIN NUTR METAB CARE, vol. 13, no. 3, 2010, pages 225 - 9
LEE, S.J.A.C. MCPHERRON: "Regulation of myostatin activity and muscle growth", PROC NATL ACAD SCI USA, vol. 98, no. 16, 2001, XP002957299, DOI: 10.1073/pnas.151270098
AMIROUCHE, A. ET AL.: "Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle", ENDOCRINOLOGY, vol. 150, no. 1, 2009, pages 286 - 94
WOODHOUSE, L. ET AL.: "A Phase 2 Randomized Study Investigating the Efficacy and Safety of Myostatin Antibody LY2495655 versus Placebo in Patients Undergoing Elective Total Hip Arthroplasty", J FRAILTY AGING, vol. 5, no. 1, 2016, pages 62 - 70
BECKER, C. ET AL.: "Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomized, phase 2 trial", LANCET DIABETES ENDOCRINOL, vol. 3, no. 12, 2015, pages 948 - 57
AMATO, A.A. ET AL.: "Treatment of sporadic inclusion body myositis with bimagrumab", NEUROLOGY, vol. 83, no. 24, 2014, pages 2239 - 46, XP055251705, DOI: 10.1212/WNL.0000000000001070
CUTFIELD, W. S. ET AL.: "Non-compliance with growth hormone treatment in children is common and impairs linear growth", PLOS ONE., vol. 6, no. 1, 2011, pages e16223
BANG, P. ET AL.: "Identification and management of poor response to growth-promoting therapy in children with short stature", CLIN ENDOCRINOL (OXF, vol. 77, no. 2, 2012, pages 169 - 181
PUCHE, J.E.I. CASTILLA-CORTAZAR: "Human conditions of insulin-like growth factor-I (IGF-I) deficiency", J TRANSL MED, vol. 10, 2012, pages 224, XP021134203, DOI: 10.1186/1479-5876-10-224
KOHN, A.D. ET AL.: "Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation", J BIOL CHEM, vol. 271, no. 49, 1996, pages 31372 - 8, XP002558471, DOI: 10.1074/jbc.271.49.31372
CHO, H. ET AL.: "Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta", SCIENCE, vol. 292, no. 5522, 2001, pages 1728 - 31, XP002974608, DOI: 10.1126/science.292.5522.1728
GREEN, C.J. ET AL.: "Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake", J BIOL CHEM, vol. 283, no. 41, 2008, pages 27653 - 67, XP055102593, DOI: 10.1074/jbc.M802623200
GARCIA-FERNANDEZ, M. ET AL.: "Low doses of insulin-like growth factor I improve insulin resistance, lipid metabolism, and oxidative damage in aging rats", ENDOCRINOLOGY, vol. 149, no. 5, 2008, pages 2433 - 42
PUCHE, J.E. ET AL.: "Low doses of insulin-like growth factor-I induce mitochondrial protection in aging rats", ENDOCRINOLOGY, vol. 149, no. 5, 2008, pages 2620 - 7
JOSEPH D'ERCOLE, A.P. YE: "Expanding the mind: insulin-like growth factor I and brain development", ENDOCRINOLOGY, vol. 149, no. 12, 2008, pages 5958 - 62
ABUZZAHAB, M.J. ET AL.: "IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation", N ENGL J MED, vol. 349, no. 23, 2003, pages 2211 - 22
WOODS, K.A. ET AL.: "Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene", N ENGL J MED, vol. 335, no. 18, 1996, pages 1363 - 7
PEREZ, R. ET AL.: "Mitochondrial protection by low doses of insulin-like growth factor- I in experimental cirrhosis", WORLD J GASTROENTEROL, vol. 14, no. 17, 2008, pages 2731 - 9
KANG, B.P. ET AL.: "IGF-I inhibits the mitochondrial apoptosis program in mesangial cells exposed to high glucose", AM J PHYSIOL RENAL PHYSIOL, vol. 285, no. 5, 2003, pages F1013 - 24
BHASKAR, V. ET AL.: "A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control", DIABETES, vol. 61, no. 5, 2012, pages 1263 - 71, XP055325190, DOI: 10.2337/db11-1578
XIONG, L. ET AL.: "Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor", PROC NATL ACAD SCI USA, vol. 89, no. 12, 1992, pages 5356 - 60, XP002423617, DOI: 10.1073/pnas.89.12.5356
RUNNELS, H.A. ET AL.: "Human monoclonal antibodies to the insulin-like growth factor 1 receptor inhibit receptor activation and tumor growth in preclinical studies", ADV THER, vol. 27, no. 7, 2010, pages 458 - 75, XP002751208, DOI: 10.1007/s12325-010-0026-5
SOOS, M.A. ET AL.: "A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity", J BIOL CHEM, vol. 267, no. 18, 1992, pages 12955 - 63, XP002477383
KATO, H. ET AL.: "Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3", J BIOL CHEM, vol. 268, no. 4, 1993, pages 2655 - 61, XP008114108
ATZORI,F.: "A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors", CLIN CANCER RES., vol. 17, no. 19, 2011, pages 6304 - 12
DE BONO J.S. ET AL.: "Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer", CLIN CANCER RES., vol. 20, no. 7, 2014, pages 1925 - 34
TAKETO TANAKA ET AL., KEIO J. MED., vol. 60, pages 37 - 46
KABAT ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 147, no. 5, 1991, pages 1709 - 1719
AL-LAZIKANI ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 273, no. 4, 1997, pages 927 - 948
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1992, DIANE PUBLISHING
EDELMAN ET AL., PROC. NATL. ACAD. SCI USA, vol. 63, 1969, pages 78 - 85
MILSTEIN ET AL., NATURE (ENGLAND, vol. 305, no. 5934, 6 October 1983 (1983-10-06), pages 537 - 540
MILSTEIN ET AL., NATURE, vol. 305, no. 5934, 1983, pages 537 - 540
TAKETO TANAKA ET AL., THE KEIO JOURNAL OF MEDICINE, vol. 60, pages 37 - 46
"University of the Sciences in Philadelphia", 2000, LIPPINCOTT WILLIAMS & WILKINS, article "Remington: The Science and Practice of Pharmacy, 20th EDITION"
H. JIANGX. GE, JOURNAL OF ANIMAL SCIENCE, vol. 92, 2014, pages 21 - 29
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 497
See also references of EP 3636670A4
Attorney, Agent or Firm:
AOKI, Atsushi et al. (JP)
Download PDF: